Sponsors (8)
This bill seeks to lower drug prices and increase transparency by giving HHS and enforcement agencies tools to designate and constrain "excessive" prices and to enable open licensing and faster generic/biosimilar entry—but those benefits come with meaningful risks to innovation incentives, increased administrative and legal burdens, possible market disruptions, and heightened compliance costs.
Millions of patients (especially those with chronic conditions) and public payers will likely pay lower prices for some brand drugs because the bill lets HHS identify 'excessive' prices, cap royalties, and authorize open non‑exclusive licenses that enable cheaper generic/biosimilar entry.
Medicare, Medicaid, and taxpayers could see reduced public spending on high‑cost drugs as price constraints, competition, and revenue clawbacks deter excessive pricing.
Patients, payers, researchers, and policymakers will gain much greater transparency on pricing decisions, petitions, determinations, company revenues, R&D and clinical‑trial investments, improving oversight and informed decision‑making.
Brand manufacturers and investors may face materially lower returns and weakened exclusivity, which could reduce incentives and funding for future drug R&D and slow the pace of new drug development.
Some manufacturers may respond by delaying, limiting, or withdrawing U.S. product launches or restricting patient access to new therapies, risking slower availability of improved treatments for patients.
The bill creates substantial administrative, legal, and implementation burdens for HHS, FTC, FDA, courts, and manufacturers (reporting, determinations, licensing, litigation), likely raising government costs, causing backlogs, and diverting agency resources.
Based on analysis of 8 sections of legislative text.
Directs HHS to flag excessively priced brand drugs by international or multi-factor tests, strip exclusivities, authorize non-exclusive licenses with royalties, require detailed manufacturer reporting, and enforce penalties.
Introduced May 20, 2025 by Bernard Sanders · Last progress May 20, 2025
Requires HHS to review brand-name drug prices each year and label drugs as "excessively priced" if U.S. prices exceed a median of five reference countries or based on other factors. For drugs found excessive, the Secretary can strip government-granted exclusivities, allow open non-exclusive regulatory licenses for generics/biosimilars with reasonable royalties, force prioritized review of follow-on applications, and pursue civil recovery for interim price hikes. Creates an FDA public database of findings, requires detailed annual manufacturer price and cost reporting (with penalties for late or false reports), bars coordinated anticompetitive actions meant to block the law, and directs penalties to support NIH research grants. The law sets timelines for reviews, reporting, royalty-setting rules to keep prices below the excessive threshold, and mechanisms to allocate royalties among patent/investor holders.